We recently compiled a list of the 10 Firms Kick Off 2025 Trading in The Red. In this article, we are going to take a look at where Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) stands against the other stocks.
The stock market finished the first trading day of the year in the negative territory—a fifth straight day, over the lack of catalysts to spark trading appetite.
The Dow Jones Industrial Average was down the most by 0.36 percent, the S&P 500 decreased 0.22 percent, and the Nasdaq Composite dipped 0.16 percent.
Ten companies also kicked off trading mirroring the broader market downturn. In this article, let’s explore the reasons behind their decline.
To come up with Thursday’s top losers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.
A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company.
Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA)
Shares of Teva Pharmaceuticals fell for a third day on Thursday, shedding another 3.34 percent or 0.74 points to finish at $21.3 apiece, as investors awaited further developments on its schizophrenia treatment Tev’749.
While the asset showed statistical improvement in schizophrenia symptoms during its Phase III trial, some experts raised concerns about the drug’s twice-daily dosing schedule, saying that the effectiveness of treatment often hinges on consistent medication, which can be particularly challenging for patients with schizophrenia.
In other news, the company recently made progress with its Duvakitug drug, developed with its French counterpart Sanofi, which met its primary goals of treating ulcerative colitis and Crohn’s disease.
Last year, the two firms announced a partnership to develop treatments for inflammatory bowel disease (IBD), with hopes that the drug could achieve a blockbuster status and generate at least $1 billion in annual sales.
Overall TEVA ranks 9th on our list of the stocks that crashed yesterday. While we acknowledge the potential of TEVA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TEVA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.